Phlyctenular Keratoconjunctivitis

Comprehensive Clinical Guide: Phlyctenular Keratoconjunctivitis (PKC)

Phlyctenular Keratoconjunctivitis (PKC) represents a localized, immunologically mediated inflammatory condition of the ocular surface. It is clinically characterized by the formation of "phlyctenules"—small, elevated, grayish-white nodules that typically manifest at the limbus or on the bulbar conjunctiva. Unlike infectious keratitis, PKC is not a primary infection of the ocular tissue; rather, it is a hypersensitivity reaction, most commonly directed against microbial antigens.

This guide serves as a definitive resource for clinicians, ophthalmologists, and medical researchers in understanding the multifaceted nature of this condition, from its underlying immunological triggers to the clinical management of its potentially sight-threatening sequelae.

1. Deep-Dive: Etiology and Pathophysiology

The pathophysiology of PKC is fundamentally rooted in a Type IV (delayed-type) hypersensitivity reaction. The ocular surface acts as a site of immune engagement where sensitized T-lymphocytes react to specific exogenous antigens.

The Antigenic Trigger

The most frequent association historically and clinically is with Mycobacterium tuberculosis. In endemic regions, tuberculosis remains the primary etiological suspect. However, in developed nations, the spectrum of triggers has shifted significantly.

The Mechanism of Action

1. Sensitization Phase: The host is initially exposed to the microbial antigen, leading to the sensitization of T-cells.
2. Re-exposure: Upon subsequent exposure (or persistent presence of the antigen), the sensitized T-cells migrate to the conjunctiva or cornea.
3. Inflammatory Cascade: These cells release pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interferon-gamma (IFN-γ).
4. Nodule Formation: This recruitment of mononuclear cells, lymphocytes, and neutrophils results in the formation of the characteristic phlyctenule—a necrotic infiltrate of the superficial stroma or epithelium.

2. Clinical Presentation and Staging

PKC manifests with a range of symptoms that correlate with the severity of the inflammatory response. Patients typically present with intense ocular discomfort, photophobia, and a foreign body sensation.

Clinical Signs

• The Phlyctenule: Begins as a small, pinkish-gray nodule.
• Vascularization: A leash of dilated blood vessels often accompanies the lesion, extending from the limbus toward the phlyctenule.
• Location: Most commonly at the limbus, though bulbar and corneal locations are documented.
• Corneal Involvement: If the phlyctenule migrates onto the cornea, it may leave a "phasic" trail of superficial scarring known as a "roving phlyctenule."

Grading and Classification

While there is no formal universal grading scale, clinicians generally classify PKC based on the extent of corneal involvement:

1. Conjunctival PKC: Limited to the bulbar conjunctiva; excellent prognosis, resolves without scarring.
2. Limbal PKC: Located at the corneal-scleral junction; can cause localized thinning.
3. Corneal PKC: Involves the corneal stroma; carries the highest risk of ulceration, neovascularization, and permanent visual acuity reduction.

3. Diagnostic Approach and Differential Diagnosis

Diagnosing PKC requires a high index of suspicion and a thorough investigation of the patient’s systemic health.

Key Diagnostic Workup

• Slit-Lamp Biomicroscopy: Essential for identifying the distinct nodular morphology and assessing the depth of corneal involvement.
• Systemic Screening:
  • PPD (Purified Protein Derivative) Test or IGRA: Mandatory to rule out pulmonary or extrapulmonary tuberculosis.
  • Chest X-Ray: To identify latent or active TB.
  • Eyelid Margin Examination: To assess for Staphylococcal blepharitis (the leading non-TB cause).

Differential Diagnosis Table

4. Therapeutic Management Strategies

The management of PKC is dual-pronged: treating the acute ocular inflammation and addressing the underlying systemic or localized antigenic source.

Acute Management

• Topical Corticosteroids: The gold standard for rapid resolution. Low-potency steroids (e.g., Fluorometholone) are often sufficient, though Prednisolone Acetate 1% may be required for severe corneal involvement.
• Antibiotic Coverage: If Staphylococcus blepharitis is identified, aggressive lid hygiene (warm compresses, lid scrubs) and topical antibiotics (Bacitracin or Erythromycin ointment) are critical to prevent recurrence.

Long-Term Management

• Addressing TB: If the patient is PPD positive, referral to an infectious disease specialist for anti-tubercular therapy (e.g., Isoniazid) is mandatory.
• Immunomodulation: In recalcitrant cases, systemic immunosuppression may be considered, though this is rarely necessary.

5. Prognosis and Complications

The prognosis for PKC is generally favorable, especially when diagnosed early.
* Conjunctival lesions heal without sequelae.
* Corneal lesions can result in superficial stromal scarring, lipid deposition, and peripheral corneal neovascularization, which may induce astigmatism or chronic visual disturbances.
* Complications: Recurrence is common if the underlying Staphylococcal blepharitis or systemic infection is not adequately controlled.

6. Frequently Asked Questions (FAQ)

1. Is Phlyctenular Keratoconjunctivitis contagious?
No. PKC is a hypersensitivity reaction, not an infectious disease itself. However, the underlying cause (like TB) may be contagious, necessitating systemic evaluation.

2. Why do phlyctenules cause so much pain?
The cornea is one of the most densely innervated tissues in the body. The inflammatory process disrupts the epithelium and stimulates nerve endings, leading to intense photophobia and pain.

3. Can I wear contact lenses during an active outbreak?
Absolutely not. Contact lens wear must be discontinued immediately to prevent secondary bacterial superinfection and to allow the ocular surface to heal.

4. Is surgery ever required?
Surgery is almost never required for the phlyctenule itself. It is only indicated in rare cases of severe peripheral corneal thinning or impending perforation.

5. How long does it take for a phlyctenule to heal?
With appropriate topical steroid treatment, most phlyctenules show significant improvement within 48 to 72 hours.

6. Does PKC affect both eyes?
It can be bilateral, but it is frequently unilateral at the time of initial presentation.

7. Can children get PKC?
Yes, PKC has historically been referred to as a disease of childhood, particularly in areas where tuberculosis is prevalent.

8. Will I lose my vision permanently?
If treated promptly, visual loss is rare. Permanent vision loss only occurs if the phlyctenule leads to significant central corneal scarring or severe astigmatism.

9. What is the role of eyelid hygiene?
Since Staphylococcus is a common trigger, keeping the eyelid margins clean reduces the bacterial load, thereby reducing the antigenic stimulus that causes the hypersensitivity reaction.

10. What should I do if my symptoms return?
Recurrence is a hallmark of PKC. You must return to your ophthalmologist for a repeat evaluation to determine if the antigenic trigger has changed or if the initial treatment was insufficient.

7. Risks, Side Effects, and Contraindications

While topical steroids are highly effective, they are not without risk. Clinicians must be vigilant regarding:
* Steroid-Induced Glaucoma: Chronic use can lead to elevated intraocular pressure.
* Cataract Formation: Prolonged corticosteroid use is associated with posterior subcapsular cataracts.
* Secondary Infection: Steroids suppress local immunity; hence, they must be used cautiously if there is a suspicion of active herpetic or fungal keratitis.

Contraindications

• Active Epithelial Herpes Simplex Keratitis: Steroids will cause rapid worsening and potential corneal perforation.
• Known Hypersensitivity to Corticosteroids: Rare, but necessitates the use of alternative anti-inflammatory agents like topical NSAIDs or cyclosporine.

Conclusion

Phlyctenular Keratoconjunctivitis remains a classic example of how systemic immune responses manifest in ocular tissue. By maintaining a high index of suspicion for underlying Staphylococcal blepharitis or tuberculosis, the clinician can effectively manage the acute inflammatory phase and prevent long-term structural damage to the cornea. Consistent patient education regarding the chronic nature of the condition and the importance of lid hygiene is paramount to ensuring sustained ocular health.